Cellectar Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Cellectar Biosciences, Inc. (CLRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $2.04 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-04
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $2.04M, a 61.82% decline from fiscal 2024.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $5.34M, a 219.74% increase from fiscal 2023.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $1.67M, a 24.61% increase from fiscal 2022.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $1.34M, a 149.50% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 134 month |
|---|---|---|---|
| 2025-12-31 | $2.04M 10-K · filed 2026-03-04 | ||
| 2024-12-31 | $5.34M 10-K · filed 2026-03-04 | ||
| 2023-12-31 | $1.67M 10-K · filed 2025-03-13 | $1.65M 10-K · filed 2024-03-27 | |
| 2022-12-31 | $1.34M 10-K/A · filed 2024-10-29 | $712.43K 10-K · filed 2023-03-09 | |
| 2021-12-31 | $537.45K 10-K · filed 2023-03-09 | ||
| 2020-12-31 | $389.40K 10-K · filed 2022-03-21 | ||
| 2019-12-31 | $715.59K 10-K · filed 2021-03-02 | ||
| 2018-12-31 | $416.73K 10-K · filed 2020-03-09 | ||
| 2017-12-31 | $636.07K 10-K · filed 2019-02-26 | ||
| 2016-12-31 | $440.44K 10-K · filed 2018-03-21 | ||
| 2015-12-31 | $449.65K 10-K · filed 2017-03-15 | ||
| 2014-12-31 | $936.31K 10-K/A · filed 2016-10-20 | ||
| 2013-12-31 | $2.11M 10-K · filed 2015-05-20 | $6.46M 10-K · filed 2014-03-19 | |
| 2012-12-31 | $1.55M 10-K · filed 2014-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |